Efficacy, safety and pharmacokinetic results of an ongoing international phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) with ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects at 48 weeks

被引：0
|
作者：
DeJesus, E. [1 ]
Orkin, C. [2 ]
Rockstroh, J. [3 ]
Molina, J-M [4 ]
White, K. [5 ]
Wei, X. [5 ]
Plummer, A. [5 ]
Kearney, B. [5 ]
Cheng, A. [5 ]
机构：
[1] Orlando Immunol Ctr, Orlando, FL USA
[2] Barts & London NHS Trust, London, England
[3] Univ Bonn, Bonn, Germany
[4] St Louis Hosp, Paris, France
[5] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
HIV MEDICINE | 2012年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [31] Ninety-six-week efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF - subgroup analyses by baseline HIV-1 RNA and CD4 cells.
    Zolopa, Andrew
    Rockstroh, Jurgen
    Orkin, Chloe
    Stellbrink, Hans-Jurgen
    Walmsley, Sharon
    Cooper, David
    Zhong, Lijie
    Fordyce, Marshall
    Rhee, Martin
    Bernstein, Mark
    Hindman, Jason T.
    Szwarcberg, Javier
    [J]. PHARMACOTHERAPY, 2013, 33 (10): : E210 - E211
  • [32] Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
    Orkin, Chloe
    Eron, Joseph J.
    Rockstroh, Juergen
    Podzamczer, Daniel
    Esser, Stefan
    Vandekerckhove, Linos
    Van Landuyt, Erika
    Lathouwers, Erkki
    Hufkens, Veerle
    Jezorwski, John
    Opsomer, Magda
    [J]. AIDS, 2020, 34 (05) : 707 - 718
  • [33] Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial
    Arribas, Jose R.
    Pialoux, Gilles
    Gathe, Joseph
    Di Perri, Giovanni
    Reynes, Jacques
    Tebas, Pablo
    Thai Nguyen
    Ebrahimi, Ramin
    White, Kirsten
    Piontkowsky, David
    [J]. LANCET INFECTIOUS DISEASES, 2014, 14 (07): : 581 - 589
  • [34] Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
    Orkin, Chloe
    Molina, Jean-Michel
    Negredo, Eugenia
    Arribas, Jose R.
    Gathe, Joseph
    Eron, Joseph J.
    Van Landuyt, Erika
    Lathouwers, Erkki
    Hufkens, Veerle
    Petrovic, Romana
    Vanveggel, Simon
    Opsomer, Magda
    [J]. LANCET HIV, 2018, 5 (01): : E23 - E34
  • [35] Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive patients with HIV-1: subgroup analyses of the phase 3 AMBER study
    Rashbaum, Bruce
    Spinner, Christoph D.
    McDonald, Cheryl
    Mussini, Cristina
    Jezorwski, John
    Luo, Donghan
    Van Landuyt, Erika
    Brown, Kimberley
    Wong, Eric Y.
    [J]. HIV RESEARCH & CLINICAL PRACTICE, 2019, 20 (01) : 24 - 33
  • [36] A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
    Eron, Joseph J.
    Orkin, Chloe
    Gallant, Joel
    Molina, Jean-Michel
    Negredo, Eugenia
    Antinori, Andrea
    Mills, Anthony
    Reynes, Jacques
    Van Landuyt, Erika
    Lathouwers, Erkki
    Hufkens, Veerle
    Jezorwski, John
    Vanveggel, Simon
    Opsomer, Magda
    [J]. AIDS, 2018, 32 (11) : 1431 - 1442
  • [37] Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study
    Baldin, G.
    Ciccullo, A.
    Capetti, A.
    Rusconi, S.
    Sterrantino, G.
    Cossu, M. V.
    Giacomelli, A.
    Lagi, F.
    Latini, A.
    Bagella, P.
    De Luca, A.
    Di Giambenedetto, S.
    Madeddu, G.
    [J]. HIV MEDICINE, 2019, 20 (02) : 164 - 168
  • [38] Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks (vol 379, pg 2439, 2012)
    Sax, P. E.
    DeJesus, E.
    Mills, A.
    [J]. LANCET, 2012, 380 (9843): : 730 - 730
  • [39] Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naive HIV-1-infected patients (the ARTEN study)
    Podzamczer, D.
    Andrade-Villanueva, J.
    Clotet, B.
    Taylor, S.
    Rockstroh, J. K.
    Reiss, P.
    Domingo, P.
    Gellermann, H. J.
    de Rossi, L.
    Cairns, V.
    Soriano, V.
    [J]. HIV MEDICINE, 2011, 12 (06) : 374 - 382
  • [40] Strategic simplification: the efficacy and safety of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) plus darunavir (DRV) in treatment-experienced HIV-1 infected adults (NCT01968551)
    Huhn, G.
    Gallant, J.
    Wilkin, T.
    Callebaut, C.
    Fordyce, M.
    Das, M.
    Mccallister, S.
    Yau, S.
    [J]. HIV MEDICINE, 2016, 17 : 15 - 15
12345